Welcome to our dedicated page for ATAI Life Sciences N.V. Common Shares news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on ATAI Life Sciences N.V. Common Shares stock.
ATAI Life Sciences N.V. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of mental health disorders. Based in the United States and Germany, ATAI leverages a decentralized, technology- and data-driven platform to serve millions suffering from mental health challenges. The company’s mission is to develop innovative treatments that address significant unmet medical needs, leading to paradigm shifts in mental health care.
ATAI's product pipeline includes promising candidates such as COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. These candidates are designed to treat conditions such as depression, anxiety, addiction, and other mental health disorders.
Recently, ATAI announced positive results from its Phase 1 study of EMP-01, the R-enantiomer of MDMA. The study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EMP-01. Involving 32 healthy participants, the study showed that EMP-01 was well-tolerated with no severe adverse events. The PK profile was dose-proportional, and PD measures indicated significant, consistent, and dose-dependent changes. These promising results might pave the way for EMP-01’s further clinical development.
ATAI Life Sciences is committed to efficient drug development by pooling resources, expertise, and best practices across its portfolio. This approach helps mitigate risks and accelerates the development of impactful, evidence-based treatments. The company’s vision is to heal mental health disorders, enabling everyone to live a more fulfilled life.
For more information, visit their official website at www.atai.life.
atai Life Sciences announced positive initial results from the Phase 1 clinical trial of KUR-101, an oral formulation of deuterated mitragynine aimed at treating opioid use disorder (OUD). The trial showed KUR-101 is safe, well-tolerated, and produces dose-dependent analgesia without severe adverse effects. Topline results comparing KUR-101 to oxycodone are anticipated by the end of 2022. OUD affects approximately 3 million Americans, with high relapse rates. KUR-101 could offer a safer alternative in the growing global OUD market, projected to reach $4.81 billion by 2028.
atai has initiated a Phase 1 single-ascending dose (SAD) trial for its drug VLS-01, a synthetic form of DMT aimed at treating treatment-resistant depression (TRD). Topline results are expected in H1 2023. The trial will study the bioavailability of buccal versus IV formulations, safety, and tolerability. Approximately 100 million people globally suffer from TRD, highlighting the need for innovative treatments. The study incorporates atai's IDEA-1 digital therapeutic app to enhance the therapeutic experience.
atai Life Sciences (Nasdaq: ATAI) has announced its participation in several investor events in October 2022, including the Roth Inaugural Healthcare Opportunities Conference and Cantor Fitzgerald’s Neurology & Psychiatry Conference. The company aims to transform mental health treatment and will also host a virtual R&D Day on October 25, 2022. During the virtual event, key opinion leaders will discuss innovative approaches to treating mental health disorders. Archived webcasts will be accessible for up to 90 days on atai’s website.
atai Life Sciences has received regulatory and ethics approvals to start a Phase 1 trial for EMP-01, an MDMA derivative targeting PTSD. This trial will evaluate the safety and tolerability of EMP-01 in 32 healthy volunteers. The randomized, double-blind study aims to assess single-ascending doses and the usability of the IDEA-1 app. Current FDA-approved treatments for PTSD show limited efficacy, which emphasizes the need for new therapies. Topline results are expected in H2 2023.
atai Life Sciences (Nasdaq: ATAI), a clinical-stage biopharmaceutical company focused on mental health treatments, will participate in several investor conferences this September. Key events include the Citi’s BioPharma Conference on September 7, the H.C. Wainwright Global Investment Conference on September 13, the Cowen Neuropsychiatry Summit on September 19, and the Jefferies Psychedelics Summit on September 22. Presentations will be available via their website for up to 90 days.
atai Life Sciences reported a robust cash position of $312M as of June 30, 2022, boosted by a non-dilutive debt facility of up to $175M, extending its financial runway into 2025. The company has achieved several key milestones in its R&D pipeline, including the completion of a clinical phase study for PCN-101, database lock for GRX-917, and initiation of VLS-01. Expected clinical data readouts from eight programs are anticipated within the next 12 months, signaling potential significant developments in mental health treatments.
atai Life Sciences N.V. announced a term loan facility of up to $175 million with Hercules Capital to enhance its financial position in developing novel mental health treatments. This non-dilutive financing, combined with existing cash of $312 million, provides access to $487 million for advancing its drug pipeline. The funding structure includes flexible draw options and a 10.05% interest rate, maturing in 48 months. The CEO emphasized the strategic flexibility this provides for addressing unmet needs in neuropsychiatry.
atai Life Sciences, a clinical-stage biopharmaceutical company, will announce its second quarter 2022 financial results on August 15, 2022. The firm is focused on innovating treatments for mental health disorders, including depression and anxiety. A video interview with management will be available at 8:30 a.m. ET on the same day, with the recording to be accessible on their website. Founded in 2018, atai aims to accelerate drug development through a unique business model that integrates funding and regulatory expertise to tackle mental health challenges.
Kures Therapeutics, a subsidiary of atai Life Sciences (Nasdaq: ATAI), announced the appointment of Dr. Chad Beyer as CEO effective July 1, 2022. Dr. Beyer brings over 25 years of experience in CNS and neurological medication development. He has led numerous IND submissions and contributed to two blockbuster drugs. Outgoing CEO Dr. Srinivas Rao will support Kures from atai Life Sciences. Kures is focused on developing KUR-101, an innovative treatment for opioid use disorder, showing promising preclinical results without significant side effects.
atai Life Sciences N.V. (Nasdaq: ATAI) announced the appointment of Stephen Bardin as CFO Designate starting June 27, 2022. Bardin, previously Senior VP of Finance at BridgeBio Pharma, brings extensive financial expertise, including raising over USD 2B. Current CFO Greg Weaver will transition to a strategic advisory role by March 31, 2023. With a strong cash balance of USD 335M as of March 31, 2022, the company aims to advance innovative mental health treatments. CEO Florian Brand expressed confidence in Bardin's fit for the team, emphasizing the need for transformative solutions in mental health.
FAQ
What is the current stock price of ATAI Life Sciences N.V. Common Shares (ATAI)?
What is the market cap of ATAI Life Sciences N.V. Common Shares (ATAI)?
What is ATAI Life Sciences N.V.?
Where is ATAI Life Sciences based?
What are some of ATAI Life Sciences' key products?
What recent achievement has ATAI announced?
What is EMP-01?
What is the mission of ATAI Life Sciences?
How does ATAI Life Sciences accelerate drug development?
What is the vision of ATAI Life Sciences?
How can I get more information about ATAI Life Sciences?
